
    
      A randomized, multicentered, open label, comparative study to assess the efficacy and safety
      of Endolex ForteÂ® versus a combination of micronized diosmin (450 mg) and micronized
      hesperidin (50 mg) in reducing the symptomatology of patients diagnosed with Chronic Venous
      Insufficiency which is rated between functional classes CEAP 1-4, during a period of 6
      months.
    
  